MannKind Corp. (MNKD) has received FDA approval for Afrezza, an inhalation insulin powder, to be used in children and adolescents aged 6 and older with type 1 and type 2 diabetes. This marks a significant expansion of Afrezza’s market, previously limited to adult patients, and introduces a new mealtime insulin option for pediatric care. The approval is backed by data from the INHALE-1 clinical trial and extensive research on inhaled insulin spanning two decades.
This development could enhance MannKind’s market position and drive revenue growth, particularly as it opens up a new demographic of patients. The pricing strategy, offering Afrezza at $35 or less per month, may also attract families seeking affordable diabetes management solutions.
For investors, the approval presents a potential catalyst for stock performance, as increased accessibility could lead to higher sales volumes and improved earnings projections in the coming quarters.
Source: nasdaq.com